| Stage | MELI | % of rev | RCL | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $10.2B | 100.00% | $5.6B | 100.00% | MELI ×1.82 |
| Gross profit | $2.9B | 28.35% | $2.9B | 51.51% | RCL +23.2pp |
| Operating income | $683M | 6.72% | $1.9B | 33.46% | RCL +26.7pp |
| Pre-tax income | $606M | 5.96% | $1.8B | 31.51% | RCL +25.6pp |
| Net income | $466M | 4.58% | $1.7B | 31.03% | RCL +26.4pp |
| Stage | MELI | RCL | Gap · A − B |
|---|---|---|---|
| Revenue | $10.2B100.00% | $5.6B100.00% | MELI ×1.82 |
| Gross profit | 28.35%$2.9B | 51.51%$2.9B | RCL +23.2pp |
| Operating income | 6.72%$683M | 33.46%$1.9B | RCL +26.7pp |
| Pre-tax income | 5.96%$606M | 31.51%$1.8B | RCL +25.6pp |
| Net income |
| 4.58%$466M |
| 31.03%$1.7B |
| RCL +26.4pp |
No disclosed counterparties: RCL.
None